Loading stock data…
Thermo Fisher Scientific Inc (TMO)
$568.26-4.06 (-0.71%)
Market ClosedLast close Jul 24
Thermo Fisher Scientific Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Thermo Fisher Scientific Inc. in the Healthcare sector is trading at $568.26 with a market capitalization of $165.3B. Wall Street consensus targets $615.12 (26 analysts), implying a +8.2% move over the next 12 months. The stock is currently 12% below its 52-week high of $643.99, remaining 7.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +8.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.01B↓ | $12.21B↑ | $11.12B↑ | $10.85B↑ | $10.36B |
| Gross Profit | $4.43B↓ | $5.01B↑ | $4.58B↑ | $4.41B↑ | $4.24B |
| Operating Income | $1.91B↓ | $2.30B↑ | $2.08B↑ | $1.92B↑ | $1.81B |
| Net Income | $1.65B↓ | $1.96B↑ | $1.62B | $1.62B↑ | $1.51B |
Peer Comparison
JNJUNHPFE
Fundamentals
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four se...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$165.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.31%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.19%
Volume
Today's trading volume
2.44M
Recent News
Thermo Fisher Scientific's Strong Q2 Not Enough to 'Meaningfully' Change H2 Outlook, RBC Says
Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" chang
TMO Q2 Deep Dive: Broad-Based End Market Growth and Strategic Portfolio Moves
Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.
Company News for July 24, 2026
Companies in The News Are: TMO, TSLA, UNP, CSX
Reading Between The Lines Of DHR's Latest Call
Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.
Thermo Fisher raises 2026 outlook after 10% growth in Q2
Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.